1. bookVolume 29 (2021): Issue 1 (January 2021)
Journal Details
License
Format
Journal
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo

Extended panel of biomarkers for long term monitoring of effectiveness of 3 direct antiviral regimen in HCV genotype 1b infection: results from a Romanian infectious disease hospital

Published Online: 29 Jan 2021
Page range: 93 - 103
Received: 14 Sep 2020
Accepted: 15 Nov 2020
Journal Details
License
Format
Journal
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo
Abstract

Background: Hepatitis C virus can be eradicated with antiviral therapy, thus reducing the risk of disease progression and death associated with the final stage of liver disease.

Methods: 241 patients received PrOD+RBV for 12 weeks. Clinical and laboratory data were assessed at baseline, week 4, 8, 12 (end of treatment, EOT), and 12 weeks after therapy (sustained virological response, SVR). Subsequently, biological and virological measurements were performed at least 48 weeks after obtaining SVR12 in responder patients.

Results: Per protocol SVR12 rate was 97,6%. Severe adverse events were reported in 3 patients (1.24%) and led to treatment discontinuation (liver decompensation). One 58-year-old patient who completed the treatment died before SVR evaluation due to acute mesenteric ischemia (not related to antiviral therapy). Baseline total bilirubin above 2 mg/dl can be considered a predictive factor for non-response to PrOD+RBV treatment (p = 0.004). Of the 30 patients evaluated at least 48 weeks after SVR no one presented relapses, with no statistically significant differences in biological parameters changes and no adverse events were noted during the 48-week follow up period.

Conclusion: Our study revealed the high effectiveness and good safety profile of PrOD +RBV in patients with genotype-1b HCV compensated cirrhosis (Child Pugh A) which were maintained during a 48-week period after treatment finalization.

Keywords

1. Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis 2008;12:661–74. DOI: 10.1016/j.cld.2008.03.007Search in Google Scholar

2. Stanciu C, Trifan A. Hepatitis C Virus Treatment Revolution: Eastern European Story Hepat Mon 2015;15(7):e28969. DOI: 10.5812/hepatmon.28969v2Search in Google Scholar

3. Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: Treatment of difficult to treat patients. World J Hepatol 2015;7(15):1953–63. DOI: 10.4254/wjh.v7.i15.1953Search in Google Scholar

4. Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol 2018;69(3):718–35. DOI: 10.1016/j.jhep.2018.05.011Search in Google Scholar

5. Viekirax® (AbbVie). Rezumatul caracteriticilor produsului [online]. [2015] [cited 2019 December 9]; Available from: URL: https://www.ema.europa.eu/en/documents/product-information/viekirax-epar-product-information_ro.pdfSearch in Google Scholar

6. Exviera® (AbbVie). Rezumatul caracteriticilor produsului [online]. [2015] [cited 2019 December 9]; Available from: URL: https://www.ema.europa.eu/en/documents/product-information/exviera-epar-product-information_ro.pdfSearch in Google Scholar

7. Protocol terapeutic corespunzator DCI Ombitasvirum + Paritaprevirum + Ritonavirum + DCI Dasabuvirum [online]. [2015] [cited 2019 December 9]; Available from: URL: http://www.cnas.ro/page/tratament-fara-interferon-3.htmlSearch in Google Scholar

8. Streinu-Cercel A. Hepatitis C burden in Romania 2016–2017 Evaluation 2018 challenges [online]. [cited 2019 December 9]; Available from: URL: http://www.vhpb.org/files/html/Meetings_and_publications/Presentations/BUCH32.pdfSearch in Google Scholar

9. Covic A, Iancu LS, Apetrei C, Scripcaru D, Volovat C, Mititiuc LI et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999;14:40–5. DOI: 10.1093/ndt/14.1.40Search in Google Scholar

10. Gheorghe L, Iacob S, Csiki IE. Prevalence of hepatitis C in Romania. Different from European rates. J Hepatol 2008;49:658–63. DOI: 10.1016/j.jhep.2008.06.016Search in Google Scholar

11. Voiculescu M, Iliescu L, Ionescu C, Micu L, Ismail G, Zilisteanu D et al. A Cross-Sectional Epidemiological Study of HBV, HCV, HDV and HEV Prevalence in the SubCarpathian and South-Eastern Regions of Romania. J Gastrointestin Liver Dis 2010; 19(1):43–8.Search in Google Scholar

12. European Centre for Disease Prevention and Control. Hepatitis C. In: ECDC. Annual epidemiological report for 2016 [online]. [2018] [cited 2019 December 9]; Available from: URL: https://www.ecdc.europa.eu/en/publications-data/hepatitis-c-annual-epidemiological-report-2016Search in Google Scholar

13. Popovici O, Molnar GB, Popovici F, Janţă D, Pistol A, Azoicăi D. A Seroprevalence Study of Hepatitis B and C Virus Infections in a Hospitalized Population in Romania, an Opportunity for a Better National Prevention and Control Strategy. J Gastrointestin Liver Dis 2016;25(1):25–32. DOI: 10.15403/jgld.2014.1121.251. hbcSearch in Google Scholar

14. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31(2):30–60. DOI: 10.1111/j.1478-3231.2011.02539.xSearch in Google Scholar

15. Ahmed H, Abushouk AI, Menshawy A, Mohamed A, Negida A, Loutfy SA et al. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis. Clin Drug Investig 2017;37(11):1009–23. DOI: 10.1007/s40261-017-0565-5Search in Google Scholar

16. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973–82. DOI: 10.1056/NEJMoa1402869Search in Google Scholar

17. Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C et al. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine 2017;96(50):e9271. DOI: 10.1097/MD.0000000000009271Search in Google Scholar

18. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A et al. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol 2017;2:427–34. DOI: 10.1016/S2468-1253(17)30048-1Search in Google Scholar

19. Danilau D, Malich N, Litvinchuk D, Karpov I. Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus. Clin Exp Hepatol 2017;3(3):164–68. DOI: 10.5114/ceh.2017.70281Search in Google Scholar

20. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New England J Med 2014;370:1604–14. DOI: 10.1056/NEJMoa1401561Search in Google Scholar

21. Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. Clin Infect Dis 2015;60:608−10. DOI: 10.1093/cid/ciu865Search in Google Scholar

22. Calleja JL, Rincon D, Ruiz-Antoran B, Sacristan B, Perello C, Lens S et al. Effectiveness and safety of ombitasvir and paritaprevir, ritonavir and dasabuvir patients with genotype 1 chronic hepatitis C virus infection: results from Spanish real world cohort. J Hepatol 2016; 64(2):218–19. DOI: 10.1016/S0168-8278(16)00189-6Search in Google Scholar

23. Agarwal K, Gaeta GB, Lee SS, Dumas EO, A Streinu-Cercel, E Schote et al. Long-term clinical outcomes in HCV genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: First interim safety and efficacy results from TOPAZ-I [online]. [2016] [cited 2019 December 9]; Available from: URL: http://www.natap.org/2016/AASLD/AASLD_54.htmSearch in Google Scholar

24. Preda CM, Popescu CP, Baicus C, Voiosu TA, Manuc M, Pop CS et al. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis. Liver Int 2018;38(4):602–10. DOI: 10.1111/liv.13550Search in Google Scholar

25. Dinu S, Țârdei G, Ceauşu E, Florescu SA, Micu L, Ecobici AM et al. Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania. Rev Romana Med Lab. 2018;26(4):443–9. DOI: 10.2478/rrlm-2018-0029Search in Google Scholar

Plan your remote conference with Sciendo